VPIM
ITCI

Vanguard Personalized Indexing Management’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Vanguard Personalized Indexing Management’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-8,280
Closed -$1.09M – 2054
2025
Q1 		$1.09M Buy
8,280
+1,242
+18% +$155K 0.02% 740
2024
Q4 		$588K Sell
7,038
-62
-0.9% -$5.09K 0.01% 1033
2024
Q3 		$520K Buy
7,100
+788
+12% +$59.2K 0.01% 1077
2024
Q2 		$432K Buy
6,312
+1,052
+20% +$73K 0.01% 1099
2024
Q1 		$364K Sell
5,260
-120
-2% -$8.25K 0.01% 1177
2023
Q4 		$385K Buy
5,380
+1,434
+36% +$82.5K 0.01% 1129
2023
Q3 		$206K Buy
3,946
+455
+13% +$26.5K 0.01% 1293
2023
Q2 		$221K Buy
+3,491
New +$218K 0.01% 1283

Other funds holding ITCI

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
KIM
Kestra Investment Management Austin, Texas $5.8B AUM 14.71% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Vanguard Personalized Indexing Management's ITCI Position: Q2 2025 in Review

Vanguard Personalized Indexing Management sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 8,280 shares — an estimated $1.09M sold.

Vanguard Personalized Indexing Management first reported a position in ITCI in Q2 2023 and held it in 8 quarters. The position peaked at $1.09M in Q1 2025. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

  • Vanguard Personalized Indexing Management reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
  • Vanguard Personalized Indexing Management sold 8,280 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $1.09M.
  • Vanguard Personalized Indexing Management first reported a position in Intra-Cellular Therapies Inc. in Q2 2023 and held it in 8 quarters.
  • Vanguard Personalized Indexing Management's Intra-Cellular Therapies Inc. position peaked at $1.09M in Q1 2025.
  • 4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on Vanguard Personalized Indexing Management's 13F filing for Q2 2025, filed 25 Jul 2025.